AGBL2 and rheumatoid arthritis: The relative distinctions between anti–CEP‐1 and anti‐cTNC5 prompted us to ask whether testing for these 2 fine specificities in combination with anti‐CCP2 would be clinically useful in improving diagnosis or identifying clinical subsets among patients with RA.